$21.190
-0.714 (-3.37%)Al cierre
Rentabilidad y márgenes de GPCR
Evaluating the bottom line, Structure Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -20.21%, provide a clear picture of how effectively GPCR converts its operational activities into shareholder value.
Comparativa sectorial de GPCR
In the context of the broader market, GPCR competes directly with industry leaders such as INVA and OCUL. With a market capitalization of $1.51B, it holds a significant position in the sector. When comparing efficiency, GPCR's gross margin of N/A stands against INVA's 75.77% and OCUL's 85.08%. Such benchmarking helps identify whether Structure Therapeutics Inc. is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Structure Therapeutics Inc
The company has shown significant losses, with a net income of -106,159,000 USD in Q2 2026 and an EPS of -0.49, indicating ongoing financial struggles.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.